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Backgrounds: Pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) is associated
with poor prognosis. Recently echocardiography and brain natriuretic peptide (BNP) have been
used as non-invasive markers for PH suggesting that they may also be used as markers for
survival. The aim of this study was to evaluate the clinical usefulness of echocardiography
and BNP by analyzing their association with survival.
Methods: Retrospective review of 131 patients with IPF who underwent both echocardiography
and BNP measurement at a tertiary referral center.
Results: Mean follow-up period was 10.1 months. Using systolic pulmonary arterial pressure of
40 mmHg as a threshold for PH, patients with PH had poor survival (1-year mortality rate:
61.2%, mean survival: 10.8 months) than those without PH (19.9%, 23.7 months; p< 0.001).
The prognosis of the subjects with increased BNP levels was poorer than those with normal
BNP levels (1-year mortality rate: 70.5% vs. 23.7%, mean survival: 11.0 months vs. 22.5 months;
p< 0.001) and on multivariate analysis, only BNP level was an independent predictor of prog-
nosis. On serial evaluation, the survival of patients with newly developed PH and/or elevated
BNP levels was similar to that of patients with PH at the initial measurement, suggesting that
development of PH is indicative of poor prognosis regardless of the timing of the test.
Conclusions: Although both BNP level and PH by echocardiography are clinically useful non-
invasive and easily repeatable markers of prognosis, BNP level seems to be better.
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The prognostic value of echocardiography and brain natriuretic peptide in idiopathic pulmonary fibrosis 181Introduction approved by the Institutional Review Board of the AsanIdiopathic pulmonary fibrosis (IPF) is a disease character-
ized by progressive parenchymal fibrosis of unknown
etiology.1 There is no proven effective therapy for IPF.2 The
overall prognosis is poor, with a median survival of about 3
years3; however; the course of disease varies among indi-
vidual patients. Several factors have been reported as
prognostic predictors4e11: age, initial forced vital capacity
(FVC), diffusion capacity (DLco), serial change in FVC, and
desaturation during a 6-min walk test (6MWT). However,
recent double-blind, randomized, placebo-controlled
studies for IPF,12e14 revealed that many patients suc-
cumbed without significant prior reductions in lung func-
tion.15 Therefore, it has been suggested that, in addition to
progressive fibrosis, other factors such as acute exacerba-
tion or development of pulmonary hypertension (PH) may
play an important role in the prognosis of IPF.16e18
The development of PH is often observed in the late
stages of IPF and indicates poor prognosis. Right-heart
catheterization (RHC) is required for the definitive diag-
nosis of PH. However, RHC is invasive and difficult to
perform routinely in clinical practice. Whereas trans-
thoracic echocardiography is non-invasive and easily
repeatable enabling it as a useful tool for screening or
follow-up of PH. Furthermore, recently, brain natriuretic
peptide (BNP) has been used as a marker of right ventric-
ular dysfunction and pulmonary arterial hypertension19e22
and Leuchte et al. reported that plasma BNP levels corre-
lated well with the severity of pulmonary hemodynamic
abnormality in patients with chronic lung disease.23,24
Therefore we hypothesized that the combination of these
two non-invasive parameters may provide a better predic-
tion of the prognosis of IPF. To test this hypothesis, we
reviewed the echocardiography and BNP data of 131
patients with IPF and compared them with survival. We also
evaluated the clinical value of serial measurement of sPAP
and BNP during follow-up.Materials and methods
Study populations
Echocardiography was performed in 352 patients with IPF
(surgical lung biopsy, 49.1%) from September 1996 to July
2008 at the Asan Medical Center, Seoul, South Korea. Most of
the subjects had been included in previous clinical studies.25
Estimation of sPAP was possible in 261 patients (74.1%) and
14 patients were excluded owing to the presence of left
ventricular dysfunction (ejection fraction< 50%) due to
another cardiac problem or valvular heart disease. Among
the remaining 247 patients, plasma BNP levels were also
measured in 188 patients. In 131 of these patients, the
measurement of plasma BNP levels and echocardiography
were performed within 3-day period; these 131 patients
were enrolled in this study. All subjects met the diagnostic
criteria of the American Thoracic Society (ATS)/European
Respiratory Society (ERS) IPF guidelines,1 and other disor-
ders that could cause secondary PH were excluded. Written
consent was provided by each patient and the study wasMedical Center.
Methods
Clinical data were obtained from medical records and
survival status was obtained from telephone interviews or
medical records. Spirometry (Vmax 22; Sensormedics;
Yorba Linda, CA), lung volume by plethysmography (6200
Plethysmograph; Sensormedics) and diffusion capacity for
carbon monoxide (Vmax 229D; Sensormedics) were
measured and the results were expressed as percentages of
normal predicted values. The 6-min walk test (6MWT) was
performed according to ATS guidelines with a slight modi-
fication: the technician followed the patients with contin-
uous monitoring of oxygen saturation during the test but no
additional remark or encouragement to the patient.26
Echocardiography
Echocardiography (Hewlett-Packard Sonos 2500 or 5500
imaging system; Hewlett-Packard Inc; Palo Alto, CA) was
performed using standard transthoracic windows with
a 2.5-MHz transducer. Tricuspid regurgitant flow was iden-
tified by color-flow Doppler techniques and the maximum
jet velocity was measured by continuous-wave Doppler in
all patients. Right atrial pressure was estimated as
5 mmHg, 10 mmHg or 15 mmHg on the basis of the size and
respiratory change of the inferior vena cava (complete
collapse, 5 mmHg; partial collapse, 10 mmHg; no collapse,
15 mmHg).27 Right ventricular systolic pressure was esti-
mated based on the modified Bernoulli equation and was
considered to be equal to the sPAP in the absence of right
ventricular outflow obstruction. Receiver operating char-
acteristic (ROC) analysis revealed that a sPAP of 40 mmHg
was the threshold that could be used to discriminate
survivors from non-survivors and this value was used as
a threshold for PH diagnosis.
BNP
Plasma BNP concentration was measured using the ADVIA
Centaur CP Immunoassay System (Siemens Medical Solu-
tion Diagnostics; Tarrytown, NY, USA). To avoid an under-
estimation or over-estimation of the individual values of
BNP, the normalized ratio was calculated for each patient
as follows: measured value divided by age- and gender-
adjusted normal values. Consequently, a ratio >1 indicates
an increase in plasma BNP concentration.28
Statistical methods
All values were described as mean standard deviation or
95% confidence interval (CI). A chi-square test or Fisher’s
exact test was used for categorical data and the unpaired
Student’s t test or ManneWhitney U test for continuous
data. Survival was evaluated using a KaplaneMeier survival
curve and the log-rank test. Cox regression analysis was
used to identify significant variables predicting survival.
Variables selected by univariate analysis (p< 0.05) were
evaluated in a multivariate analysis. ROC curve analysis was
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BNP. A p-value less than 0.05 was considered statistically
significant (two-tailed). All data were analyzed using SPSS
version 12.0 (SPSS, Inc.; Chicago, IL).
Results
Demographic features of the subjects
The mean age of the study population was 64.3 years and
73.3% were male. Mean follow-up period (from echocardi-
ography to death or last follow-up) for the entire group was
10.1 months (median 10.4 months; range, 0.1e30.0 months)
(Table 1). Compared with patients without PH, patients with
PH had decreased FVC (% predicted), DLco, walking distance
and lowest oxygen saturation (SpO2) during 6MWT, and
increased BNP levels (all, p< 0.05) (Table 1). However, when
patientswith increasedBNP levelswerecomparedwith those
with normal BNP levels, the only difference between the two
groups was in the 6MWT distance (320.2 vs. 431.7 m,
respectively; pZ 0.008) (Table 1).
Prognosis of IPF patients with pulmonary
hypertension (systolic pulmonary arterial pressure
greater than 40 mmHg) detected by
echocardiography
PH was present in 25.2% of subjects. In the patients with
PH, the 1-year mortality rate (61.2%) was higher than thatTable 1 Clinical characteristics of the patients according to th
Characteristics Total sPAP
Number (%) 131 (100) 33 (25.
Age, year 64.3 8.8 65.1
Male, No. (%) 96 (73.3) 24 (72.
Follow-up, montha 10.1 6.3 7.9 6
Biopsy, No. (%) 69 (52.7) 15 (45.
Smoking, No. (%)
Never-smokers 43 (32.8) 10 (30.
Ex-smokers 69 (52.7) 18 (54.
Smokers 19 (14.5) 5 (15.2
Smoking amount, pyr 24.4 23.5 22.7
Pulmonary function test
FVC, % predicted 71.4 21.6 61.3
DLco, % predicted 59.1 22.0 33.1
TLC, % predicted 72.2 16.8 67.2
6-Min walk test
Distance, m 418.4 140.2 267.5
Lowest SpO2, % 86.5 8.2 74.8
sPAP, mmHg 37.5 17.6 61.7
BNP, pg/mlb 20.0 (2.0e3202) 34.0 (2
BNP ratiob 0.3 (0.0e30.3) 0.7 (0.
Data are presented as mean SD unless otherwise indicated. sPAPZ
BNPZ brain natriuretic peptide.
a After echocardiography.
b Data are presented as median (range).
c BNP ratio was calculated for each patient as follows: measured val
indicates an increase in plasma BNP concentration.of the patients without PH (19.9%; p< 0.001) and mean
survival time was shorter (10.8 vs. 23.7 months; p< 0.001)
(Fig. 1A). The hazard ratio of mortality in patients with PH
was 4.3 (95% CI: 2.3e8.1; p< 0.001), compared with those
without. When the patients were categorized into three
groups according to their sPAP levels, there was a corre-
lation between the levels of sPAP and mortality
(p< 0.001) (Fig. 1B). The 1-year mortality rates in
sPAP< 40 mmHg was 19.9%, sPAP: 40e59 mmHg was 47.1%
and sPAP 60 mmHg was 76.0%. The hazard ratio of
mortality in the moderate- and high-sPAP groups was 2.9
(95% CI: 1.3e6.8; pZ 0.011) and 6.1 (95% CI: 2.9e12.6;
p< 0.001) (Table 2).
Prognosis of IPF patients with elevated BNP levels
BNP levels were increased in 14.5% of subjects and the
mean survival time of the patients with increased BNP
levels was shorter (11 months) than that of the patients
with normal BNP levels (22.5 months; p< 0.001) (Fig. 2A).
The 1-year mortality rate (70.5% vs. 23.7%; p< 0.001) was
also higher in the high-BNP group and the hazard ratio of
mortality was 4.1 (95% CI: 2.1e8.0; p< 0.001), compared
with the normal-BNP group. When the subjects were
divided into three groups according to their BNP levels,
there was a correlation between the BNP levels and
mortality (p< 0.001) (Fig. 2B). The 1-year mortality rates in
BNP ratio <1 was 26.4%, BNP ratio: 1e4 was 50.0% and BNP
ratio 5 was 100%. The hazard ratio of mortality in the
moderate- and high-BNP groups was 2.2 (95% CI: 0.9e6.0;eir sPAP and BNP levels.
40 mmHg BNP ratioc 1 Combined
2) 19 (14.5) 8 (6.1)
9.4 66.7 10.6 65.0 11.8
7) 13 (68.4) 6 (75.0)
.1 7.9 8.1 4.1 3.9
5) 7 (36.8) 4 (50.0)
3) 7 (36.8) 3 (37.5)
5) 8 (42.1) 2 (25.0)
) 4 (21.1) 3 (37.5)
22.4 20.3 20.2 21.3 21.7
20.4 68.3 22.2 71.0 28.0
12.0 50.7 25.9 24.0 8.0
14.1 69.1 16.3 75.3 9.0
135.3 320.2 151.1 238.0 161.5
7.4 85.2 9.1 73.7 4.5
19.0 52.1 30.1 84.9 11.5
.0e3202) 212 (60e3202) 920.5 (67e3202)
0e30.3) 2.1 (1.0e30.3) 16.0 (1.7e30.3)
systolic pulmonary arterial pressure, SpO2Z oxygen saturation,
ue divided by age- and gender-adjusted normal values. A ratio >1
Figure 1 Survival curves of all subjects. A, comparison of the survival curves between the patients with sPAP 40 mmHg and
those with sPAP< 40 mmHg. B, comparison of the survival curves of subjects stratified according to their sPAP levels.
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respectively.
ROC analysis demonstrated that the prognostic value of
plasma BNP levels to predict mortality (area under the
curve [AUC], 0.728) was similar to that of sPAP (AUC, 0.721;
pZ 0.916).
Combination of echocardiography and BNP
The patients were categorized into three groups according
to sPAP and BNP levels: group 1: all normal, 87 patients
(66.4%); group 2: one abnormal parameter: either
increased sPAP (40 mmHg) or increased BNP, 36 patients
(27.5%); group 3: all abnormal, 8 patients (6.1%). The 1-
year mortality rate was greatest (100%) in group 3, followed
by group 2 (51.2%) and then in group 1 (15.2%), and the
differences between the groups were statistically signifi-
cant (groups 1 vs. 2, p< 0.001; groups 2 vs. 3, pZ 0.009)
(Fig. 3). The hazard ratio of mortality in groups 2 and 3 was
4.4 (95% CI: 2.2e9.1; p< 0.001) and 13.8 (95% CI: 5.3e35.8;
p< 0.001), respectively (Table 3).
Serial changes in sPAP during follow-up and survival
Among 131 patients, serial echocardiography was per-
formed in 53 patients (mean interval, 15.7 17.7 months).
Among these 53 patients, 17 had PH at initial echocardi-
ography and 36 did not have PH. On follow-upTable 2 Survival data according to sPAP levels.
Characteristics sPAP (mmHg)
<40 40e
Number (%) 98 (74.8) 18 (
1Y MR, % 19.9 47.1
Survival, month
Mean (95% CI) 23.7 (21.2e26.1) 11.8
Median (95% CI) 28.4 (13.5e43.2) 15.9
RR (95% CI) 1 2.9
RR (95% CI) 0.3 (0.1e0.8) 1
sPAPZ systolic pulmonary arterial pressure, MRZmortality rate, CIZ
a It is p-value for group with sPAP 60 mmHg. p-Value for group wi
b It is p-value for group with sPAP 60 mmHg. p-Value for group wiechocardiography, 9 (25%) of the latter 36 patients were
found to have newly developed PH. The 1-year incidence of
PH was 32%. The survival of the patients with newly
developed PH from the onset of PH was similar (1-year
mortality: 55.6%; mean survival: 7.8 months) to that of the
patients with PH at initial echocardiography (61.2%, 10.8
months; pZ 0.720). The survival of the patients persis-
tently without PH at follow-up echocardiography analysis
(1-year mortality: 18.9%; mean survival: 23.5 months) was
similar to that of the patients without PH at initial
echocardiography (19.9%, 23.7 months respectively). The
survival of the patients with newly developed PH tends to
be worse than that of patients with persistently without PH
at follow-up measurement, although the difference was not
statistically significant (pZ 0.061) probably due to small
number of the patients.
Serial changes in BNP levels during follow-up and
survival
BNP levels were measured more than twice in 62 stable
patients (mean interval, 9.6 7.0 months). Eleven patients
had increased BNP levels at the initial measurement, and
the remaining 51 patients had normal levels. Thirteen
(25.5%) of these 51 patients had increased BNP levels on
follow-up measurement and the 1-year incidence of
increased BNP levels was 29.7%. The survival of these
patients from the onset of elevation of BNP levels (1-yearp-Value
59 60
13.7) 15 (11.5)
76.0 <0.001
(8.6e15.0) 8.3 (4.4e12.2)
(9.5e22.3) 6.7 (2.5e11.0)
(1.3e6.8) 6.1 (2.9e12.6) <0.001a
2.1 (0.8e5.0) 0.115b
confidence interval, RRZ relative risk of mortality.
th sPAP of 40e59 mmHg is 0.011.
th sPAP< 40 mmHg is 0.011.
Figure 2 Survival curves of all subjects. A, comparison of the survival curves between the patients with BNP ratio 1 and those
with BNP ratio< 1. (BNP ratio: measured value of BNP divided by age- and gender-adjusted normal values.) B, comparison of the
survival curves of subjects stratified to their BNP levels. BNP ratio< 1: 1-year mortality, 26.4%; mean survival, 22.5 months (95% CI,
20.0e25.1). BNP ratio: 1e4: 1-year mortality, 50.0%; mean survival, 16.6 months (95% CI, 8.6e24.6). BNP ratio 5: 1-year
mortality, 100%; mean survival, 3.7 months (95% CI, 0.8e6.6) (p-value< 0.001 [BNP< 1 vs. 1e4, pZ 0.081; BNP 1e4 vs. 5,
pZ 0.013]).
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that of the patients with elevated BNP levels at initial
measurement (70.5%, 11 months; pZ 0.680). And the
survival of these patients with newly elevated BNP level
was significantly worse than that of patients with persis-
tently normal BNP levels at follow-up measurement (29.5%,
pZ 0.005).
Evaluation of prognostic factors
Univariate analysis revealed that sPAP and BNP levels are
significant predictors of mortality (Table 4). FVC (% pre-
dicted), DLco (% predicted), TLC (% predicted), walking
distance and SpO2 nadir during 6MWT were also significant
predictors of mortality. However, on multivariate analysis,
only BNP levels, TLC and SpO2 nadir during 6MWT were
significant independent predictors of mortality (Table 5).Figure 3 Comparison of the survival curves of subjects
stratified to their sPAP and BNP levels. Group 1:
sPAP< 40 mmHg and BNP ratio< 1. Group 2: either
sPAP 40 mmHg or BNP ratio 1. Group 3: sPAP 40 mmHg
and BNP ratio 1 (p-value< 0.001 [group 1 vs. 2, p< 0.001;
group 2 vs. 3, pZ 0.009]).Discussion
The aim of this study was to identify non-invasive methods
for predicting prognosis that can be used routinely in clin-
ical practice. We found that both BNP levels and sPAP
estimated by echocardiography were clinically useful indi-
cators of poor prognosis although on multivariate analysis,
only BNP level was an independent prognostic marker,
suggesting the superiority of BNP level over sPAP. The
combination of the two indices provided a better prediction
of prognosis than either alone. Furthermore, serial sPAP
and BNP level measurements, both of which can be easily
performed, revealed that at any time during the disease
course, increases in these parameters are predictive for
poor prognosis.
It is well known that PH is associated with shorter
survival in patients with IPF. Using RHC, the gold-standard
method, Lettieri et al.29 found an increased 1-year
mortality rate (28%) in patients with PH compared with
those without PH (5.5%; pZ 0.002), and another prospec-
tive study30 reported a higher 5-year mortality rate in
patients with PH (83.3%) than in those without PH (37.8%;
p< 0.001). However, its invasiveness and high costs limit
the routine use of RHC in clinical practice, whereas echo-
cardiography is a non-invasive and inexpensive method.
Although echocardiography is often inaccurate and leads to
considerable over-diagnosis of PH,27 it may be used as
a prognostic indicator. Nadrous et al. have reported that PH
defined as estimated sPAP> 35 mmHg by echocardiography
had a significant adverse impact on survival in a cohort of 88
patients.31 In patients with sPAP> 50 mmHg, median
survival was only 0.7 year, in contrast to more than 4 years
in patients with sPAP< 50 mmHg.31 Our results also showed
higher 1-year mortality rate (61.2%) and shorter mean
survival time in patients with sPAP 40 mmHg than in those
with sPAP< 40 mmHg. Furthermore, the degree of sPAP was
closely correlated with prognosis, as shown in Fig. 1B.
Recently, it has been known that BNP has a role not only
in left ventricular failure, but also in primary pulmonary
arterial hypertension and right ventricular overload after
acute pulmonary embolism, and it seems to be a highly
Table 3 Survival data according to combination of sPAP and BNP levels.
Characteristics Group 1 Group 2 Group 3 p-Value
Number (%) 87 (66.4) 36 (27.5) 8 (6.1)
1Y MR, % 15.2 51.2 100 <0.001
Survival, month
Mean (95% CI) 25.2 (22.7e27.8) 14.9 (10.8e19.0) 4.7 (1.4e7.9)
Median (95% CI) NA 10.7 (3.0e18.3) 1.8 (0.0e4.6)
RR (95% CI) 1 4.4 (2.2e9.1) 13.8 (5.3e35.8) <0.001a
RR (95% CI) 0.2 (0.1e0.5) 1.0 3.1 (1.3e7.6) 0.012b
MRZmortality rate, CIZ confidence interval, RRZ relative risk of mortality, NAZ not available.
a It is p-value for group3. p-Value for group 2 is <0.001.
b It is p-value for group3. p-Value for group 1 is <0.001.
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patients.19e22,32 Leuchte et al.23,24 showed that plasma BNP
level correlated with the severity of pulmonary hemody-
namic abnormality and was a good predictor of prognosis in
patients with chronic lung disease. Our study also
confirmed the prognostic value of plasma BNP level, which
was comparable to echocardiography. Actually multivariate
analysis revealed that it is better than that of sPAP by
echocardiography. Although we could not clearly demon-
strate the superiority of the combination of both parame-
ters compared to only one parameter with statistical
significance because of the small numbers of the subjects
with elevated sPAP and BNP level, our results suggested
that a combination of BNP level and sPAP may provide
a better prediction of mortality than either parameter
alone suggested by higher hazard ratio. Further study
including more patients is required to confirm this.
Furthermore, echocardiography and measurement of
BNP levels have the advantage that they can be repeated
easily. We found that the development of increased sPAP
and/or BNP levels at any stage of disease course was
predictive of poor prognosis, with higher 1-year mortality
and shorter survival from the measurement.
Whether this increased mortality in the patients with
elevated sPAP by echocardiography and/or BNP level is
really due to the development of PH is not certain. It is
plausible, but still remains as speculative because we couldTable 4 Results of univariate analysis of predictive
factors for survival.
Factors Hazard ratio 95% CI p-Value
Age 1.000 0.965e1.037 0.987
Male 1.850 0.841e4.068 0.126
Smokers 1.418 0.702e2.862 0.330
FVC, % predicted 0.953 0.934e0.973 <0.001
DLco, % predicted 0.948 0.928e0.969 <0.001
TLC, % predicted 0.939 0.913e0.966 <0.001
6MWT, distance 0.995 0.993e0.997 <0.001
6MWT, SpO2 nadir 0.897 0.861e0.934 <0.001
sPAP 1.028 1.015e1.040 <0.001
BNP ratio 1.148 1.097e1.200 <0.001
CIZ confidence interval, 6MWTZ 6-min walk test, SpO2Z
oxygen saturation, sPAPZ systolic pulmonary arterial pressure.not show the direct relationship between the degree of
sPAP and mortality due to inability to perform RHC.
Our study had several limitations. This was a retrospec-
tive review of patients evaluated at a single center. Our
hospital is a tertiary referral center and this study was
restricted to patients who underwent both echocardiog-
raphy and BNP measurement within a 3-day period.
Therefore, the subjects may not be representative of all IPF
patients. In fact, the survival of all subjects was relatively
poor (even the patients without PH), which may be due to
inclusion of patients with relatively advanced disease.
However, the presence of PH clearly indicated poorer
prognosis when compared with patients without PH. The
second limitation was a short mean follow-up period.
However, it was sufficient to reveal the prognostic value of
PH and elevated BNP levels. The other limitation is that
RHC was not performed to confirm the presence and degree
of PH resulting in over-estimation of the incidence of PH.
However, our aim is not a diagnosis of PH, but the evalua-
tion of the value of sPAP estimated by echocardiography
and BNP levels as predictors of prognosis. We think this aim
is clinically more important because, at present, there is no
proven effective treatment for PH in patients with IPF. If an
effective PH therapy with a proven survival benefit
becomes available, RHC would be indicated for more
accurate diagnosis of PH. Despite these limitations, our
study is the first attempt to evaluate the clinical role of
a combination and serial measurement of echocardiography
and BNP levels in patients with IPF.
In conclusion, our data suggest that BNP levels and sPAP
by echocardiography are clinically useful non-invasive and
easily repeatable markers of prognosis. Although they are
complementary, the BNP level seems to be better.Table 5 Results of multivariate analysis of predictive
factors for survival.
Factors Hazard ratio 95% CI p-Value
TLC, % predicted 0.956 0.931e0.982 0.001
6MWT, SpO2 nadir 0.912 0.868e0.957 <0.001
BNP ratio 1.118 1.047e1.194 0.001
Variables selected by univariate analysis (p< 0.05) were eval-
uated in a multivariate logistic regression analysis. CIZ confi-
dence interval, 6MWTZ 6-min walk test, SpO2Z oxygen
saturation.
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